Category: Lawley Announcement
Testosterone cream for postmenopausal women with HSDD submitted for UK licensing.
Perth, Australia and Guildford, England: Lawley Pharmaceuticals and its commercial partner in the UK, Andro Pharmaceuticals Ltd, are pleased to announce that a Marketing… Continue Reading →
Wishing you a Wonderful Christmas and Happy New Year
To our valued and loyal Customers, As Christmas is rapidly approaching, we would like to take this opportunity to thank you for being a… Continue Reading →
Australasian Menopause Society Congress: 9-11 September
AMS Congress 2022 Visit us in Cairns!!! The AMS is pleased to announce the 25th Annual Australasian Menopause Society Congress will be held at… Continue Reading →
Monash University: Bone Density Study
A study to prevent bone loss and restore sexual function in women with primary ovarian insufficiency Melbourne and Perth As many as 4 in… Continue Reading →
Monash University: Bone Density Study
A study to prevent bone loss and restore sexual function in women with primary ovarian insufficiency Melbourne and Perth As many as 4 in… Continue Reading →
AndroFeme 1 included on ARTG for hypoactive sexual desire dysfunction in postmenopausal women
Lawley Pharmaceuticals’ female-specific hormone cream, AndroFeme® 1, has been registered on the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →
SCAM ALERT- no Lawley job offers in USA
Over the past few days a number of people in the USA have contacted Lawley Pharmaceuticals verifying the bona fides of a work from… Continue Reading →
COVID-19 – Changes to Lawley Pharmaceuticals operations
COVID-19 – Changes to Lawley Pharmaceuticals operations During large scale health crises, the continued supply of medicines is an essential service to the community…. Continue Reading →